Skip to main content
SpringerLink
Log in

A 5-day: the favourable way?

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pierdomenico F, Esteves S, Almeida A (2013) Efficacy and tolerability of a 5-day azacytidine dose-intensified regimen in higher-risk MDS. Ann Hematol 92:1201–1206

    Article  CAS  PubMed  Google Scholar 

  2. Kaminskas E, Farrell A, Abraham S, Baird A, Hsieh LS, Lee SL, Leighton JK, Patel H, Rahman A, Sridhara R, Wang YC, Pazdur R (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11:3604–3608

    Article  CAS  PubMed  Google Scholar 

  3. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850–1856

    Article  CAS  PubMed  Google Scholar 

  4. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascotto C, Inverizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25:3503–3510

    Article  PubMed  Google Scholar 

  5. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419–425

    Article  CAS  PubMed  Google Scholar 

  6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gatterman N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High Risk MDS Survival Study Group (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open label, phase III study. Lancet Oncol 10:223–232

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. List AF, Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Gore S, Bennett JM, Silverman LR, Backstrom J, Allen AR, Beach CL (2008) Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. J Clin Oncol. 26: Abstract 7006

Download references

Conflict of interest

The Adelaide and Meath Hospital received research support from Celgene to establish the national MDS database.

Author information

Authors and Affiliations

  1. Department of Haematology, Adelaide and Meath Hospital Incorporating the National Children’s Hospital, Dublin, 24, Ireland

    Cathy McHale, Niamh O’Connell, John McHugh, Pamela Evans & Helen Enright

  2. Department of Haematology, Beaumont Hospital, Beaumont Road, Dublin, 9, Ireland

    Maeve A. O’Reilly, Ahmed Almazmi, Philip Murphy, John Quinn, Patrick Thornton & Jeremy Sargent

  3. Department of Haematology, Mater Misericordiae Hospital, Dublin, 7, Ireland

    Abdul Hameed, Dalia Benjamin, Peter O’Gorman & Estelle Verburgh

  4. Department of Haematology, Letterkenny General Hospital, County Donegal, Ireland

    Hana Frankova

Authors
  1. Maeve A. O’Reilly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathy McHale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed Almazmi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Abdul Hameed
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dalia Benjamin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Niamh O’Connell
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Philip Murphy
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Patrick Thornton
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Peter O’Gorman
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hana Frankova
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Jeremy Sargent
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Estelle Verburgh
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. John McHugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Pamela Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Helen Enright
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maeve A. O’Reilly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

O’Reilly, M.A., McHale, C., Almazmi, A. et al. A 5-day: the favourable way?. Ann Hematol 93, 1619–1620 (2014). https://doi.org/10.1007/s00277-013-2005-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-013-2005-9

Keywords

Search

Navigation